IP Verse

Cladribine Regimen For Treating Multiple Sclerosis

Patent No. EP2805723 (titled "Cladribine Regimen For Treating Multiple Sclerosis") was filed by Merck Serono on Dec 20, 2005. The application was issued on Jan 17, 2018.

Patent Summary

Oral Cladribine treatment regimen for multiple sclerosis that allows reduced dosing and fewer side effects compared to IV or SC administration. The regimen involves multiple cycles of 1-7 days of oral Cladribine followed by Cladribine-free periods. The total Cladribine dose is lower during maintenance periods. This sequential oral dosing reduces side effects while still providing MS lesion suppression.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKOct 16, 2018ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2805723

MERCK SERONO
Application Number
EP14001970A
Filing Date
Dec 20, 2005
Status
Revoked
Oct 17, 2023
Publication Date
Jan 17, 2018
External Links
Slate, Register , Google Patents